The overexpression of CRLF2, which leads to constitutive activation of JAK2–STAT5, correlates with high-risk BCP-ALL and promotes poorer recurrence-free survival rates in pediatric patients [68,73,74]. Here, CRLF2 is linked to acute lymphoblastic leukemia.